| Ms Laura Dunn, MOT, OTR/L | |
|
3488 Jeffco Blvd Ste 102, Arnold, MO 63010-6015 | |
| (636) 464-5439 | |
| Not Available |
| Full Name | Ms Laura Dunn |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 3488 Jeffco Blvd Ste 102, Arnold, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053691840 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 2011025273 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Laura Dunn, MOT, OTR/L 3734 Linhorst Rd, Hillsboro, MO 63050-3820 Ph: (314) 406-0794 | Ms Laura Dunn, MOT, OTR/L 3488 Jeffco Blvd Ste 102, Arnold, MO 63010-6015 Ph: (636) 464-5439 |
News Archive
Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced interim findings from the ongoing phase 2 clinical study of its investigational new drug PEGPH20 for the potential treatment of patients with metastatic pancreatic cancer.
American Specialty Health Incorporated, a national health and wellness organization, recently announced that it had won four Gold and two Silver Aster awards for excellence in healthcare marketing and advertising. The Aster Awards, one of the largest national competitions of its kind, is hosted by Marketing Healthcare Today Magazine and Creative Images, Inc.
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA.
Pharmasset, Inc. announced today that dosing has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 200mg QD and 400mg QD in combination with pegylated interferon alfa 2a and ribavirin, the current standard of care (SOC) in patients with HCV genotype 1 who have not been treated previously.
The World Health Organisation (WHO) has warned that a virus that has killed 24 young children and infected more than 5,000 could continue to spread regardless of efforts to contain it.
› Verified 4 days ago
Tessa Dickinson, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3488 Jeffco Blvd Ste 102, Arnold, MO 63010 Phone: 636-464-5439 Fax: 636-464-5438 | |
Mrs. Jane E Lackner, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4 Arnold Mall, Arnold, MO 63010 Phone: 636-282-0056 Fax: 636-282-0057 | |
Brittany Nicole Hettick, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3488 Jeffco Blvd Ste 102, Arnold, MO 63010 Phone: 464-636-5439 | |
Ms. Kathryn English Petri, OT/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3488 Jeffco Blvd Ste 102, Arnold, MO 63010 Phone: 636-464-5439 Fax: 636-464-5438 | |
Mrs. Andrea Elizabeth Horsford, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1101 W Outer 21 Rd, Arnold, MO 63010 Phone: 636-296-9200 | |
Mrs. Heather Milford, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3488 Jeffco Blvd Ste 103a, Arnold, MO 63010 Phone: 636-464-5439 |